Harrow (HROW) Hisse Fiyat

Harrow Fiyat

NASDAQ·KAPALI
28,75
​
Pazar kapalı

Harrow, son 13 yılda gelirini yıllık %83,8 artırarak 272,30 M USD seviyesine taşıdı. Harrow için net marj, %-1,9 ile birkaç yıl önceki %-24,8 seviyesine göre yükseldi. Harrow için 12 aylık konsensüs fiyat hedefi 70,00 USD; bu, hissenin bugünkü fiyatının yaklaşık %143,5 üzerinde bir seviyeye denk geliyor. 15 analistten 14 tanesi hisse için alım öneriyor — genel konsensüs: Al.

Harrow hisse senedi fiyatı

Bu verilere Eulerpool API üzerinden ulaşın

Ayda 100.000 ücretsiz istek · kredi kartı yok

Harrow iş modeli ve hisse analizi

Harrow Health Inc, San Diego merkezli bir sağlık şirketidir ve yenilikçi tıbbi ürünlerin geliştirilmesi, üretimi ve pazarlanmasında uzmanlaşmıştır. Şirket, 2012 yılında Imprimis Pharmaceuticals olarak kurulmuş olup, o zamandan beri sağlık piyasasında önemli bir oyuncu haline gelmiştir.

Harrow hakkında sık sorulan sorular

Harrow Health Inc is a pharmaceutical company that operates on a unique business model. They specialize in acquiring and commercializing branded prescription drugs. By acquiring smaller pharmaceutical companies and their products, Harrow Health Inc focuses on improving patient access to vital medications. Their business strategy involves developing partnerships, managing intellectual property, and conducting research to ensure the availability of necessary medications. Through this model, Harrow Health Inc aims to address unmet medical needs and offer innovative solutions to patients. This approach enables the company to play a significant role in the pharmaceutical industry and deliver impactful healthcare products.

Harrow Health Inc is primarily active in the healthcare industry.

The main competitors of Harrow Health Inc in the market include pharmaceutical companies such as Johnson & Johnson, Pfizer Inc, and Novartis AG.

Harrow Health Inc, formerly known as Imprimis Pharmaceuticals, is a pharmaceutical company specializing in the development and commercialization of innovative therapeutic products. Founded in 2006, the company initially focused on providing compounded medications to patients and physicians. Over the years, Harrow Health Inc expanded its portfolio, acquiring multiple ophthalmology-focused businesses and broadening its reach within the eye care industry. Today, the company's offerings include both FDA-approved and compounded medications, along with proprietary formulations and drug delivery technologies. Harrow Health Inc continues to demonstrate its commitment to improving patient access to high-quality, affordable healthcare solutions within the pharmaceutical sector.

Harrow Health Inc has accomplished several significant milestones in its history. Firstly, the company successfully expanded its pharmaceutical portfolio by acquiring Imprimis Pharmaceuticals, which greatly enhanced its product offering and market presence. Additionally, Harrow Health Inc implemented strategic partnerships and collaborations to further its growth and innovation. The company also achieved financial milestones by consistently delivering positive financial results and increasing its revenue over time. Furthermore, Harrow Health Inc demonstrated its commitment to advancing patient care by successfully launching innovative drugs and expanding its prescription services. These achievements highlight Harrow Health Inc's continuous progress, strong market position, and dedication to improving healthcare outcomes.

Harrow Health Inc is primarily present in the United States.

Harrow Health Inc represents values of innovation, patient care, and ethical practices. The company strives to develop and deliver high-quality medications and healthcare solutions that improve patient outcomes and advance medical treatments. Harrow Health Inc is committed to providing accessible and affordable pharmaceuticals while maintaining strict regulatory compliance. With a focus on research and development, the company aims to address unmet medical needs and introduce pioneering therapies to enhance overall patient well-being. Harrow Health Inc's corporate philosophy revolves around integrity, transparency, and putting patients first, driving its mission to make a significant impact in the healthcare industry.

Analistler şu anda Harrow hissesi için ortalama 73,67 USD hedef fiyat belirliyor (medyan: 70,00 USD); bu, son fiyata göre +158,1 % anlamına gelir. Konsensüs 15 analist notuna dayanır.

15 analist şu anda Harrow hissesini değerlendiriyor: 14 al, 1 tut, 0 sat öneriyor. 2026 için analistler Harrow şirketinin 350,28 M USD gelir ve -0,07 USD hisse başına kâr üretmesini bekliyor.

Güncel döviz kuruyla Harrow hissesi 25,58 EUR (28,75 USD) seviyesindedir.

Harrow hissesi (HROW) 1 borsada işlem görür, bunlar arasında: NASDAQ (HROW).

Harrow Health Inc is a company that specializes in the development, marketing, and sale of high-quality pharmaceuticals and medical devices. Its business model is focused on the field of ophthalmology medicine, which is a specialized niche with a high demand for innovative products and services. The company offers its products and services in various areas, including the development of eye drops and steroids. It works closely with doctors and other medical professionals to understand the needs of patients in this area and develop innovative solutions that deliver better results for patients. Another important area in which the company operates is the production of eye implants and lenses suitable for patients with a variety of eye conditions. The different types of lenses range from intraocular lenses for vision correction to multifocal lenses for older patients. Harrow Health is also active in the production of medical devices and offers a wide range of products that can be used for eye treatment. The company manufactures medical instruments for use in surgeries, diagnostic instruments for early detection of eye diseases, and even devices for data processing and analysis. One of Harrow Health's standout products is the Buccolam medication, which was developed for the treatment of epilepsy in children and adults. Buccolam is a fast-acting seizure medication offered in a rapidly dispersible formulation and is an incredibly effective treatment for seizures. Overall, the company relies on a diversified business model to ensure that it can respond to market needs while also building a stable and sustainable business. By focusing on multiple areas of ophthalmology medicine and offering a wide range of products and services, Harrow Health ensures that it can serve a variety of customers and operate very successfully in the market. In summary, Harrow Health is a strong company that specializes in pharmaceutical and medical technology for eye care. With its wide range of products such as eye drops, implants, and medical instruments, the company ensures that it can respond to the needs of patients in this field and remain relevant to ophthalmology medicine.

beklenen'nin Harrow hasılatı 350,28 M USD'dir. Bu rakam, mevcut finansal verilere dayanmakta ve şirketin iş performansını yansıtmaktadır.

beklenen'nin Harrow karı -2,70 M USD'dir. Net kar, tüm giderleri düştükten sonra şirketin kârlılığını gösterir.

Harrow'nin Fiyat/Kazanç (F/K) oranı şu anda -392,05'dir. F/K oranı, cari hisse fiyatını hisse başına kazançla karşılaştırır ve yatırımcıların Harrow hisse senedinin değerlemesini değerlendirmelerine yardımcı olur.

Harrow'nin Fiyat/Satış (F/S) oranı şu anda 3,02'dir. F/S oranı, pazar kapitalizasyonunu yıllık gelirle karşılaştırır ve Harrow hisse senedinin değerleme metriği olarak hizmet eder.

Harrow'nin Eulerpool Kalite Puanı 6/10'dur.

Harrow'nin ISIN'i US4158581094'dir. ISIN (Uluslararası Menkul Kıymetler Kimlik Numarası), menkul kıymetler için küresel olarak benzersiz bir tanımlayıcıdır.

Harrow'nin WKN'i A2PBJD'dir. WKN (Wertpapierkennnummer), menkul kıymetleri tanımlamak için kullanılan altı haneli bir Alman kimlik numarasıdır.

Harrow'nin ticker'ı HROW'dir. Ticker sembolü, Harrow hisseleri borsada işlem görmek için kullanılır.

Adil DeğerTerminal
25,30 USD
Aşırı-/Eksik DeğerlemeTerminal
Adil Değerlenmiş
Sektor
Sektör
İlaç Sektörü
Hisse Sayısı
Çalışan Sayısı
Çalışan Başına Ciro
730.034,85 USD
Gelir Büyümesi Ø5 Yıl
EBIT Büyümesi Ø5 Yıl
Net Kar Büyümesi Ø5 Yıl
Web Sitesi imprimisrx.com
Para Birimi
USD
Halka Arz
8 Şub 2013
ISIN
US4158581094
CUSIP
415858109
SEDOL
BHNDW86
Pazar Kapitalizasyonu
1,06 Md USDSmall Cap
52 Haftalık Aralık
AAQS
6 / 10
PEG
—
F/K Oranı 2026
-392,05
F/K Oranı 2027
13,19
F/K Oranı 2028
7,30
F/K Oranı 2029
4,86
F/K Oranı 2030
4,00
P/S
F/S Oranı
3,02
EV/EBIT
29,89
KBV
20,15
ROIC
-1,74 %
Son güncelleme 5 Kas 2026 11:42

Harrow Ticker

NASDAQ · HROW

Harrow FIGI

HROW:US · BBG000QXWY44HROW:UA · BBG000QXWYK6HROW:UC · BBG000QXWYP1HROW:UN · BBG000QXWZB3HROW:UP · BBG000QXWZK3HROW:UQ · BBG000QXX001HROW:UB · BBG000QXX0B9HROW:UM · BBG000QXX118HROW:UX · BBG000QXX1F3HROW:UD · BBG000QXX4D9HROW:UF · BBG000QXX591HROW:VY · BBG000QXX5F4

Harrow'nin tüm temel göstergeleri ve derinlemesine analizi

Harrow hissesine yönelik aktienanalizimiz, satış, kar, P/E oranı, P/S oranı, EBIT gibi önemli mali kriterleri içermekte olup, dividende bilgilerini de ele almaktadır. Ayrıca, hisseler, piyasa değeri, borçlar, özsermaye ve Harrow şirketin yükümlülükleri gibi konuları incelemekteyiz. Bu konular hakkında daha detaylı bilgilere ihtiyacınız varsa, web sitemizin alt sayfalarında kapsamlı analizler sunuyoruz: